146 related articles for article (PubMed ID: 7817796)
1. The bone-remodeling transient: implications for the interpretation of clinical studies of bone mass change.
Heaney RP
J Bone Miner Res; 1994 Oct; 9(10):1515-23. PubMed ID: 7817796
[TBL] [Abstract][Full Text] [Related]
2. The basis for the post-parathyroidectomy increase in bone mass.
Heaney RP
J Bone Miner Res; 2002 Nov; 17 Suppl 2():N154-7. PubMed ID: 12412794
[TBL] [Abstract][Full Text] [Related]
3. Bisphosphonate effects and the bone remodeling transient.
Heaney RP; Yates AJ; Santora AC
J Bone Miner Res; 1997 Aug; 12(8):1143-51. PubMed ID: 9258743
[TBL] [Abstract][Full Text] [Related]
4. The mineralization of bone tissue: a forgotten dimension in osteoporosis research.
Boivin G; Meunier PJ
Osteoporos Int; 2003; 14 Suppl 3():S19-24. PubMed ID: 12730799
[TBL] [Abstract][Full Text] [Related]
5. Analogy of strain energy density based bone-remodeling algorithm and structural topology optimization.
Jang IG; Kim IY; Kwak BB
J Biomech Eng; 2009 Jan; 131(1):011012. PubMed ID: 19045928
[TBL] [Abstract][Full Text] [Related]
6. The skeleton in primary hyperparathyroidism: a review focusing on bone remodeling, structure, mass, and fracture.
Christiansen P
APMIS Suppl; 2001; (102):1-52. PubMed ID: 11419022
[TBL] [Abstract][Full Text] [Related]
7. Skeletal actions of intermittent parathyroid hormone: effects on bone remodelling and structure.
Compston JE
Bone; 2007 Jun; 40(6):1447-52. PubMed ID: 17045858
[TBL] [Abstract][Full Text] [Related]
8. [Bone remodeling].
Lerner UH; Ljunggren O
Lakartidningen; 2006 Oct 4-10; 103(40):2972-5. PubMed ID: 17115661
[No Abstract] [Full Text] [Related]
9. A simulation model at trabecular level to predict effects of antiresorptive treatment after menopause.
van der Linden JC; Verhaar JA; Pols HA; Weinans H
Calcif Tissue Int; 2003 Dec; 73(6):537-44. PubMed ID: 14508627
[TBL] [Abstract][Full Text] [Related]
10. Osteoporosis: new hope for the future.
Masi L; Bilezikian JP
Int J Fertil Womens Med; 1997; 42(4):245-54. PubMed ID: 9309458
[TBL] [Abstract][Full Text] [Related]
11. Is bone mineral density predictive of fracture risk reduction?
Cefalu CA
Curr Med Res Opin; 2004 Mar; 20(3):341-9. PubMed ID: 15025843
[TBL] [Abstract][Full Text] [Related]
12. Role of biochemical markers of bone turnover as prognostic indicator of successful osteoporosis therapy.
Reginster JY; Collette J; Neuprez A; Zegels B; Deroisy R; Bruyere O
Bone; 2008 May; 42(5):832-6. PubMed ID: 18316258
[TBL] [Abstract][Full Text] [Related]
13. Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both?
Bonnick SL; Shulman L
Am J Med; 2006 Apr; 119(4 Suppl 1):S25-31. PubMed ID: 16563938
[TBL] [Abstract][Full Text] [Related]
14. [Osteoporosis].
Guañabens N
Med Clin (Barc); 1994 Mar; 102(9):346-53. PubMed ID: 8164464
[No Abstract] [Full Text] [Related]
15. Effects of exercise training on bone remodeling, insulin-like growth factors, and bone mineral density in postmenopausal women with and without hormone replacement therapy.
Milliken LA; Going SB; Houtkooper LB; Flint-Wagner HG; Figueroa A; Metcalfe LL; Blew RM; Sharp SC; Lohman TG
Calcif Tissue Int; 2003 Apr; 72(4):478-84. PubMed ID: 12574871
[TBL] [Abstract][Full Text] [Related]
16. The effects of risedronate on canine cancellous bone remodeling: three-dimensional kinetic reconstruction of the remodeling site.
Boyce RW; Paddock CL; Gleason JR; Sletsema WK; Eriksen EF
J Bone Miner Res; 1995 Feb; 10(2):211-21. PubMed ID: 7754801
[TBL] [Abstract][Full Text] [Related]
17. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis.
Ozmen B; Kirmaz C; Aydin K; Kafesciler SO; Guclu F; Hekimsoy Z
Eur Cytokine Netw; 2007 Sep; 18(3):148-53. PubMed ID: 17823083
[TBL] [Abstract][Full Text] [Related]
18. Evidence that treatment with risedronate in women with postmenopausal osteoporosis affects bone mineralization and bone volume.
Fratzl P; Roschger P; Fratzl-Zelman N; Paschalis EP; Phipps R; Klaushofer K
Calcif Tissue Int; 2007 Aug; 81(2):73-80. PubMed ID: 17612779
[TBL] [Abstract][Full Text] [Related]
19. A randomised, double-blinded, placebo-controlled, trial to determine the individual response in bone turnover markers to lasofoxifene therapy.
Rogers A; Glover SJ; Eastell R
Bone; 2009 Dec; 45(6):1044-52. PubMed ID: 19665601
[TBL] [Abstract][Full Text] [Related]
20. [Differential therapy of osteoporosis--an overview based on recent findings regarding the pathogenesis].
Schacht E
Z Rheumatol; 1994; 53(5):274-98. PubMed ID: 7810237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
